|
1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scott CB, Scarantino C, Urtasun R, Movsas
B, Jones CU, Simpson JR, Fischbach AJ and Curran WJ Jr: Validation
and predictive power of Radiation Therapy Oncology Group (RTOG)
recursive partitioning analysis classes for malignant glioma
patients: A report using RTOG 90-06. Int J Radiat Oncol Biol Phys.
40:51–55. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jackson CM, Lim M and Drake CG:
Immunotherapy for brain cancer: Recent progress and future promise.
Clin Cancer Res. 20:3651–3659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilson TA, Karajannis MA and Harter DH:
Glioblastoma multiforme: State of the art and future therapeutics.
Surg Neurol Int. 5:642014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oike T, Suzuki Y, Sugawara K, Shirai K,
Noda SE, Tamaki T, Nagaishi M, Yokoo H, Nakazato Y and Nakano T:
Radiotherapy plus concomitant adjuvant temozolomide for
glioblastoma: Japanese mono-institutional results. PLoS One.
8:e789432013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Messaoudi K, Clavreul A and Lagarce F:
Toward an effective strategy in glioblastoma treatment. Part I:
Resistance mechanisms and strategies to overcome resistance of
glioblastoma to temozolomide. Drug Discov Today. 20:899–905.
2015.
|
|
9
|
Messaoudi K, Clavreul A and Lagarce F:
Toward an effective strategy in glioblastoma treatment. Part II:
RNA interference as a promising way to sensitize glioblastomas to
temozolomide. Drug Discov Today. 20:772–779. 2015.
|
|
10
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang PH, Xu AM and White FM: Oncogenic
EGFR signaling networks in glioma. Sci Signal. 2:re62009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paz A, Haklai R, Elad-Sfadia G, Ballan E
and Kloog Y: Galectin-1 binds oncogenic H-Ras to mediate Ras
membrane anchorage and cell transformation. Oncogene. 20:7486–7493.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burton EC, Lamborn KR, Forsyth P, Scott J,
O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, et
al: Aberrant p53, mdm2, and proliferation differ in glioblastomas
from long-term compared with typical survivors. Clin Cancer Res.
8:180–187. 2002.PubMed/NCBI
|
|
14
|
Wang AL, Liu ZX, Li G and Zhang LW:
Expression and significance of P53 protein and MDM-2 protein in
human gliomas. Chin Med J (Engl). 124:2530–2533. 2011.PubMed/NCBI
|
|
15
|
Kato H, Kato S, Kumabe T, Sonoda Y,
Yoshimoto T, Kato S, Han SY, Suzuki T, Shibata H, Kanamaru R and
Ishioka C: Functional evaluation of p53 and PTEN gene mutations in
gliomas. Clin Cancer Res. 6:3937–3943. 2000.PubMed/NCBI
|
|
16
|
Babashah S and Soleimani M: The oncogenic
and tumour suppressive roles of microRNAs in cancer and apoptosis.
Eur J Cancer. 47:1127–1137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mizoguchi M, Guan Y, Yoshimoto K, Hata N,
Amano T, Nakamizo A and Sasaki T: Clinical implications of
microRNAs in human glioblastoma. Front Oncol. 3:192013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Toledo F and Wahl GM: Regulating the p53
pathway: In vitro hypotheses, in vivo veritas. Nat Rev Cancer.
6:909–923. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Robles AI and Harris CC: Clinical outcomes
and correlates of TP53 mutations and cancer. Cold Spring Harb
Perspect Biol. 2:a0010162010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hermisson M, Klumpp A, Wick W, Wischhusen
J, Nagel G, Roos W, Kaina B and Weller M: O6-methylguanine DNA
methyltransferase and p53 status predict temozolomide sensitivity
in human malignant glioma cells. J Neurochem. 96:766–776. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Chen JX, Liu YH, You C and Mao Q:
Mutant TP53 enhances the resistance of glioblastoma cells to
temozolomide by up-regulating O(6)-methylguanine
DNA-methyltransferase. Neurol Sci. 34:1421–1428. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nie E, Jin X, Wu W, Yu T, Zhou X, Zhi T,
Shi Z, Zhang J, Liu N and You Y: BACH1 promotes temozolomide
resistance in glioblastoma through antagonizing the function of
p53. Sci Rep. 6:397432016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nijman SM, Luna-Vargas MP, Velds A,
Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and
functional inventory of deubiquitinating enzymes. Cell.
123:773–786. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang
K, Chen C, Xie Q, Mack SC, Wang X, et al: Deubiquitinase USP13
maintains glioblastoma stem cells by antagonizing FBXL14-mediated
Myc ubiquitination. J Exp Med. 214:245–267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li M, Chen D, Shiloh A, Luo J, Nikolaev
AY, Qin J and Gu W: Deubiquitination of p53 by HAUSP is an
important pathway for p53 stabilization. Nature. 416:648–653. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang CL, Wang JY, Liu ZY, Ma XM, Wang XW,
Jin H, Zhang XP, Fu D, Hou LJ and Lu YC: Ubiquitin-specific
protease 2a stabilizes MDM4 and facilitates the p53-mediated
intrinsic apoptotic pathway in glioblastoma. Carcinogenesis.
35:1500–1509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Berger FG, Yang J and Lu X: USP4
inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO
J. 30:2177–2189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z, Hao Q, Luo J, Xiong J, Zhang S, Wang
T, Bai L, Wang W, Chen M, Wang W, et al: USP4 inhibits p53 and
NF-κB through deubiquitinating and stabilizing HDAC2. Oncogene.
35:2902–2912. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Zhou F, Drabsch Y, Gao R,
Snaar-Jagalska BE, Mickanin C, Huang H, Sheppard KA, Porter JA, Lu
CX and ten Dijke P: USP4 is regulated by AKT phosphorylation and
directly deubiquitylates TGF-β type I receptor. Nat Cell Biol.
14:717–726. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hwang SJ, Lee HW, Kim HR, Lee H, Shin CH,
Yun SI, Lee DH, Kim DH, Kim KK, Joo KM and Kim HH:
Ubiquitin-specific protease 4 controls metastatic potential through
β-catenin stabilization in brain metastatic lung adenocarcinoma.
Sci Rep. 6:215962016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu C, Liu C, Liu H, Gong L, Tao T, Shen
Y, Zhu S and Shen A: Increased expression of ubiquitin-specific
protease 4 participates in neuronal apoptosis after intracerebral
hemorrhage in adult rats. Cell Mol Neurobiol. 37:427–435. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fraser M, Leung BM, Yan X, Dan HC, Cheng
JQ and Tsang BK: p53 is a determinant of X-linked inhibitor of
apoptosis protein/Akt-mediated chemoresistance in human ovarian
cancer cells. Cancer Res. 63:7081–7088. 2003.PubMed/NCBI
|
|
34
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Romanowska M, Evans A, Kellock D, Bray SE,
McLean K, Donandt S and Foerster J: Wnt5a exhibits layer-specific
expression in adult skin, is upregulated in psoriasis, and
synergizes with type 1 interferon. PLoS One. 4:e53542009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Masui K, Cloughesy TF and Mischel PS:
Review: Molecular pathology in adult high-grade gliomas: From
molecular diagnostics to target therapies. Neuropathol Appl
Neurobiol. 38:271–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schiebe M, Ohneseit P, Hoffmann W,
Meyermann R, Rodemann HP and Bamberg M: Analysis of mdm2 and p53
gene alterations in glioblastomas and its correlation with clinical
factors. J Neurooncol. 49:197–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Birner P, Piribauer M, Fischer I,
Gatterbauer B, Marosi C, Ungersböck K, Rössler K, Budka H and
Hainfellner JA: Prognostic relevance of p53 protein expression in
glioblastoma. Oncol Rep. 9:703–707. 2002.PubMed/NCBI
|
|
40
|
Kraus JA, Wenghoefer M, Glesmann N, Mohr
S, Beck M, Schmidt MC, Schröder R, Berweiler U, Roggendorf W, Diete
S, et al: TP53 gene mutations, nuclear p53 accumulation, expression
of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic
factors in de novo glioblastoma multiforme. J Neurooncol.
52:263–272. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rich JN, Hans C, Jones B, Iversen ES,
McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR
and West M: Gene expression profiling and genetic markers in
glioblastoma survival. Cancer Res. 65:4051–4058. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li Y, Jiang D, Zhang Q, Liu X and Cai Z:
Ubiquitin-specific protease 4 inhibits breast cancer cell growth
through the upregulation of PDCD4. Int J Mol Med. 38:803–811. 2016.
View Article : Google Scholar : PubMed/NCBI
|
